Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Targeting folate receptors to treat invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, Rothenbuhler R, Leamon CP, Parker N, Klein PJ, Vlahov IR, Reddy JA, Koch M, Murphy L, Fourez LM, Stewart JC, Knapp DW.

Cancer Res. 2013 Jan 15;73(2):875-84. doi: 10.1158/0008-5472.CAN-12-2101. Epub 2012 Nov 29.

2.

DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Hahn NM, Waddell J, Olbricht GR, Zheng R, Stewart JC, Knapp DW.

Urol Oncol. 2013 Nov;31(8):1761-9. doi: 10.1016/j.urolonc.2012.03.015. Epub 2012 May 19.

PMID:
22609058
3.

Assessment of folate receptor expression and folate uptake in multicentric lymphomas in dogs.

Childress MO, Dhawan D, Leamon CP, Miller MA, Ramos-Vara JA, Naughton JF, Low PS, Knapp DW.

Am J Vet Res. 2014 Feb;75(2):187-94. doi: 10.2460/ajvr.75.2.187.

PMID:
24471755
4.

Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.

Dhawan D, Paoloni M, Shukradas S, Choudhury DR, Craig BA, Ramos-Vara JA, Hahn N, Bonney PL, Khanna C, Knapp DW.

PLoS One. 2015 Sep 9;10(9):e0136688. doi: 10.1371/journal.pone.0136688. eCollection 2015.

5.
6.

Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.

Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL, Knapp DW.

Mol Cancer Ther. 2003 Feb;2(2):183-8.

7.

Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.

Knapp DW, Glickman NW, Widmer WR, DeNicola DB, Adams LG, Kuczek T, Bonney PL, DeGortari AE, Han C, Glickman LT.

Cancer Chemother Pharmacol. 2000;46(3):221-6.

PMID:
11021739
8.

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.

Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP.

Cancer Res. 2007 Jul 1;67(13):6376-82.

9.

Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).

Chun R, Knapp DW, Widmer WR, Glickman NW, DeNicola DB, Bonney PL.

J Am Vet Med Assoc. 1996 Nov 1;209(9):1588-91.

PMID:
8899023
10.

In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.

Fani M, Tamma ML, Nicolas GP, Lasri E, Medina C, Raynal I, Port M, Weber WA, Maecke HR.

Mol Pharm. 2012 May 7;9(5):1136-45. doi: 10.1021/mp200418f. Epub 2012 Apr 23.

PMID:
22497506
11.

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.

Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.

Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25.

PMID:
19779718
12.

Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.

Liang X, Sun Y, Zeng W, Liu L, Ma X, Zhao Y, Fan J.

Bioorg Med Chem. 2013 Jan 1;21(1):178-85. doi: 10.1016/j.bmc.2012.10.044. Epub 2012 Nov 3.

PMID:
23177726
13.

Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.

Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I.

Cancer Res. 2008 Dec 1;68(23):9839-44. doi: 10.1158/0008-5472.CAN-08-2341.

14.

Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.

Yang JJ, Kularatne SA, Chen X, Low PS, Wang E.

Mol Pharm. 2012 Feb 6;9(2):310-7. doi: 10.1021/mp200483t. Epub 2012 Jan 9.

PMID:
22171616
15.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.

Clin Cancer Res. 2001 Sep;7(9):2840-53.

16.

In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.

Mishra G, Hazari PP, Kumar N, Mishra AK.

J Drug Target. 2011 Nov;19(9):761-9. doi: 10.3109/1061186X.2011.561857. Epub 2011 Mar 22.

PMID:
21425922
17.

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.

Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C.

Cancer. 2009 Sep 15;115(18):4110-7. doi: 10.1002/cncr.24460.

18.

Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.

Arnold EJ, Childress MO, Fourez LM, Tan KM, Stewart JC, Bonney PL, Knapp DW.

J Vet Intern Med. 2011 Nov-Dec;25(6):1385-90. doi: 10.1111/j.1939-1676.2011.00796.x. Epub 2011 Sep 13.

19.

Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.

Fisher RE, Siegel BA, Edell SL, Oyesiku NM, Morgenstern DE, Messmann RA, Amato RJ.

J Nucl Med. 2008 Jun;49(6):899-906. doi: 10.2967/jnumed.107.049478. Epub 2008 May 15.

20.

Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.

Henry CJ, McCaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, Straw RC, Dernell WS, Madewell BR, Jorgensen L, Scott MA, Higginbotham ML, Chun R.

Clin Cancer Res. 2003 Feb;9(2):906-11.

Supplemental Content

Support Center